|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With PCR, we looked for BCR/ABL transcripts in 30 patients with CML and 4 with essential thrombocythaemia at time of diagnosis, finding a significant difference in the platelet counts of CML patients carrying b3a2 or b2a2 transcripts.
|
7718325 |
1995 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that chromosome 1 abnormalities are most frequent in BCR-ABL-negative classic myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
20002154 |
2010 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We set-up a multiplex real-time polymerase chain reaction assay followed by capillary electrophoresis, designed to simultaneously screen the two main genetic lesions associated with CMDs, i.e. the BCR-ABL fusion characteristic of chronic myeloid leukemia and the JAK2 V617F mutation that characterises polycythaemia vera and a proportion of cases of essential thrombocythemia and idiopathic myelofibrosis.
|
17285276 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
We detected the messenger RNA expression of the bcr-abl gene using reverse transcription-polymerase chain reaction in peripheral-blood leukocytes (PBLs) from 63 patients with myeloproliferative disorders (including CML, ET, and polycythemia vera [PV]) and 51 normal, healthy volunteers.
|
14966468 |
2004 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We conclude that it is important to look for BCR-ABL transcript in Ph-neg ET patients and to follow them closely to investigate the nature of this translocation in this group of patients.
|
9326244 |
1997 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also report preliminary results of our attempt to examine concordance or discordance of BCR-ABL expression in the peripheral blood and bone marrow of Ph-neg ET patients.
|
10194123 |
1999 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROC curve analysis showed that a level of WT1 transcript >10 WT1 copies/10<sup>4</sup>ABL1 enabled the diagnosis of PMF with a specificity of 95.8% (PMF vs ET; ROC AUC = 0.91).
|
30612065 |
2019 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of our study together with a review of literature data suggest that different BCR/ABL transcript variants may occur in CML mimicking ET, without an apparently significant prevalence of one type.
|
9460506 |
1998 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnosis and management of the BCR-ABL-negative myeloproliferative disorders (MPDs) of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are at an explosive crossroads of scientific investigation and evolving paradigms since the discovery of the tyrosine kinase-activating JAK2V617F mutation in 2005.
|
18024651 |
2007 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current study reported cases of two patients with an initial diagnosis of ET in the presence of JAK2V617F mutation and BCR‑ABL translocation by fluorescent in situ hybridization.
|
29845291 |
2018 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET).
|
29134817 |
2017 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The classical BCR-ABL1-negative myeloproliferative neoplasms (MPN) include essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).
|
26933174 |
2016 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BCR/ABL-negative myeloproliferative neoplasms (MPNs) of essential thrombocythemia, polycythemia vera, and primary myelofibrosis, over the natural course of their disease, have an increasing predisposition to transform to overt acute myeloid leukemia (AML)-most appropriately referred to as MPN-blast phase (MPN-BP).
|
22170483 |
2012 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), entered the spotlight in 2005 when the unique somatic acquired JAK2 V617F mutation was described in >95% of PV and in 50% of ET and PMF patients.
|
18769448 |
2008 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polycythaemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (MF), are the most common myeloproliferative neoplasms (MPN) in patients without the BCR-ABL1 gene rearrangement.
|
23986553 |
2014 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients presenting clinical features of PT expressing the Ph chromosome or the BCR/ABL fusion gene have been well documented but, to our knowledge, this is the first report of evolution from typical PT to chronic myeloid leukemia.
|
16682291 |
2006 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results confirm the absence of BCR-ABL abnormalities in Ph-negative ET patients.
|
11342314 |
2000 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Myeloproliferative neoplasms (MPN) that do not contain the BCR-ABL1 mutation include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
|
22035746 |
2011 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm diagnosed de novo or developed from essential thrombocythemia (ET) or polycythemia vera (PV).
|
22793267 |
2013 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most affected patients suffer from the classic BCR/ABL1-negative myeloproliferative disorders (MPD), especially polycythemia vera (74% of n = 506), but a subset of people with essential thrombocythemia (36% of n = 339) or myelofibrosis with myeloid metaplasia (44% of n = 127) bear the identical mutation, as do a few individuals with myelodysplastic syndromes or an atypical myeloid disorder (7% of n = 556).
|
16321848 |
2006 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
In BCR-ABL1-negative myeloproliferative neoplasms, myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia vera or essential thrombocythemia.
|
31340059 |
2019 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hence, we examined a cohort of 123 myeloproliferative neoplasm (MPN) patients without BCR-ABL1 rearrangement and additional ET patients (n=96) for coexistence of JAK2 and CALR mutations.
|
27486987 |
2016 |
|
Thrombocythemia, Essential
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic lesions such as JAK2 mutations and BCR-ABL translocation are often mutually exclusive in MPN patients and lead to essential thrombocythemia, polycythemia vera, or myelofibrosis or chronic myeloid leukemia, respectively.
|
28335073 |
2017 |
|
Thrombocythemia, Essential
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of BCR-ABL1 is critical in the distinction of ET from CML.
|
26754830 |
2016 |
|
Thrombocythemia, Essential
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
|
14966468 |
2004 |